Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Patients with rheumatoid arthritis (RA) have higher levels of serum soluble receptor for advanced glycation end product (sRAGE) compared with healthy controls, according to results published in Modern Rheumatology. The results also indicated that serum sRAGE levels positively correlated with disease activity.
The study included participants with RA (n=60) and age- and sex-matched healthy controls (n=30). The researchers performed clinical examination of participants with RA and assessed disease activity using the 28-joint Disease Activity Score. They measured serum sRAGE using enzyme-linked immunosorbent assay.
The results indicated that participants with RA had significantly higher serum sRAGE levels (median, 1000.3) compared with healthy controls (median, 293.25; P <.001).
Among participants with RA, the researchers found that there was significant difference in serum sRAGE levels according to the activity of disease (P <.001). They found significant positive correlations between serum sRAGE level with disease activity (r=.67; P <.001), erythrocyte sedimentation rate (r=.411, P =.001), and C-reactive protein level (r=.273; P =.035).
The researchers did not find any significant correlations between serum sRAGE levels and demographic characteristics or biochemical measurements, including serum creatinine, blood urea nitrogen, anticyclic citrullinated peptide, and rheumatoid factor.
“Overall, it can be concluded that sRAGE may block the ligand-RAGE interaction on the cell surface and thereby decreasing influx of inflammatory cells into the joint cavity, functioning as an immune surveillance mechanism,” the researchers wrote.
Reference
Nakhjavani MRJ, Jafarpour M, Ghorbanihagjo A, Abedi AS, Malek MA. Relationship between serum soluble receptor for advanced glycation end products (sRAGE) and disease activity in rheumatoid arthritis patients [published online November 24, 2018]. Mod Rheumatol. doi:10.1080/14397595.2018.1551107
